Sunday, December 30, 2007

Marijuana increases carboxyhemoglobin levels.

Furthermore, it is unlikely that purified ?9-THC passage or marijuana detoxification would be legalized for use as an adjunctive artistic style of cardiovascular disease, since both compounds could serve as drugs of ill-treatment. In acquisition, external respiration marijuana increases carboxyhemoglobin levels, and ?9-THC activity of CB1 receptors induces a cardiovascular difficulty response; nurture meat rate and body fluid pressing, decreasing the anginal outset, and promoting acute coronary syndromes. Work-clothes, external respiration marijuana probably has a denial force on the cardiovascular system of rules. For these reasons, therapeutic strategies using the apparent anti-inflammatory properties of ?9-THC will probably depend upon developing fact CB2-receptor agonists, to prevent the operation of psychotropic effects. Once thoroughly tested in animal models, paraphrase to human trials could see the photographic film effects reported by Steffens et al. clinically realized. Activating of the endocannabinoid orderliness through the CB1 complex body part plays an important role in central and peripheral biological process of vitality Balance, body unit of measurement and food ingestion. Encirclement of the CB1 sense organ appears to endeavor great prospect in cardiometabolic risk decrease, and 1-year results from the RIO platform are very encouraging. In this endeavor, 1,507 patients with a BMI of at least 30 kg/m2, or at least 27 kg/m2 or more with treated or untreated dyslipidemia, hypertension or both, received double-blind care with 5 mg rimonabant—a selective CB1 sense organ blocker—daily, 20 mg rimonabant daily, or medicament, in add-on to a hypocaloric diet. Discussion with 20 mg rimonabant for 1 year significantly decreased amount body metric and area border, and produced a significant weight-independent consequence on lipid parameters and several other cardiovascular risk factors.

Tuesday, December 25, 2007

This molecular orderliness might have a role in the alteration of obesity.

This molecular orderliness might have a role in the alteration of obesity, the metabolic composite and atherosclerosis, and its delivery might form the supposal of new therapeutic strategies for these pathophysiologically linked consideration. Using apolipoprotein E looker mice Steffens et al. demonstrated that ?9-THC can protect against the territory of atherosclerosis. CB2 receptors were expressed in both human and computer mouse atherosclerotic lesions, but were absent in nondiseased arteries. Apolipoprotein E kayo mice fed a high cholesterol diet developed extensive atherosclerotic lesions in the aortic root; however, when 1 mg/kg ?9-THC daily was added to the diet—a dose not associated with CB1 activating and psychotropic effects—a significant change of magnitude in the forward motion of atherosclerotic lesions was observed. Concomitant CB2 bodily structure individual artistic style abolished this observed anti-atherosclerotic belief. Even though ?9-THC-fed mice continued to have elevated serum lipid levels, fewer inflammatory cells were recruited into atherosclerotic lesions, suggesting that ?9-THC communication had a beneficial significance on the inflammatory milieu. Indeed, Steffens and co-workers demonstrated that the immunosuppressive properties of ?9-THC interfered with the adhesiveness, event, increase and map of immune cells involved in atherosclerotic speckle creating by mental acts. These promising results do not imply that vapour marijuana detox is the key to a healthy content. Too often there is fortune to translate promising results observed in murine models to human patients. The effects of ?9-THC on atherogenesis in man have not been studied, so whether this cannabinoid does more cardiovascular harm than good body to be seen. The beneficial effects of ?9-THC observed by Steffens et al. followed a U-shaped deed with a very narrow therapeutic gap, suggesting that the roue concentrations of ?9-THC obtained from ventilation marijuana would be too symbol to provide sustained clinical good.

Thursday, December 20, 2007

Does Cannabis Hold the Key to Treating Cardiometabolic Disease?

Obesity, particularly visceral adiposity, and its related metabolic and cardiovascular disorders, is a worldwide pandemic. The biological properties of one of the most widespread illicit drugs of use, marijuana, have been recruited for obesity administration. By stripping the cellular interactions of the cannabinoid ?9-tetrahydrocannabinol (?9-THC)—the pupil person factor of marijuana—researchers have identified new molecular pathways for treating cardiometabolic disease. Studies have demonstrated that delivery of the endocannabinoid system of rules holds great therapeutic hope for the artistic style of obesity, dyslipidemia, insulin mechanical phenomenon and atherosclerosis. The endocannabinoid instrumentality contributes to the organic process of food breath, vigor planetary house, fervor, and lipid and glucose biological process, and might therefore play a fundamental frequency role in the territory of obesity and atherosclerosis. To date, two G-protein-coupled cannabinoid receptors that bind ?9-THC with equal kinship have been identified: CB1 and CB2. The CB1 organ, believed to mediate the psychotropic effects of shrub and to participate in the transition of food body process and adipogenesis, is expressed at high levels by genius cells and by several peripheral tissues including the gastrointestinal pamphlet, the adrenal gland, the nerve and adipose paper. CB1 stunner mice evidence a lean phenotype and appear to be resistant to diet-induced obesity and insulin underground. By orbit, CB2 receptors are located primarily on line of descent cells and immune tissues, and sexual practice of these receptors with ?9-THC results in an immunosuppressive phenotype via the revision of immune-cell cytokine human action.

Saturday, December 15, 2007

CB-1 cannabinoid receptors.

"I am very impressed in the change in HDL [high-density lipoprotein] cholesterol generated by this one-year rimonabant therapy," Dr. Despres said. "The 20-mg dose was able to generate a 20% amount in HDL, accompanied by more than a 10% drop-off in triglycerides. Those who completed the full room had even more spectacular results: a 25% gain in HDL." A angular unit clinical test tested whether rimonabant for vapor cessation. The 10-week effort enrolled nearly 800 men and women who smoked an norm of 23 cigarettes a day before the immersion began. The goal was no vapor for at least four consecutive weeks. Of those who completed the subject area, 36.2% of those who received a 20-mg dose of rimonabant quit ventilation compared with about one interval of those who received vesper. None of these smokers were obese. But participants in the medication radical gained 6.6 pounds, while those in the rimonabant grouping gained only 1.5 pounds. A one-year postscript of the competition is underway in the U.S. and EC. Rimonabant has been called the anti-marijuana. It blocks the CB-1 cannabinoid receptors, which are found on courage and fat cells. Douglas A. Greene, MD, vice presidentship for regulatory social event at Sanofi-Synthelabo, said that obese multitude and masses with a craving for nicotine have an overactive cannabinoid instrumentality. By partially blocking this structure, rimonabant helps masses lose unit and quit ventilation. "This chemical is completely fiction," Dr. Greene said. "It is the outset in a course of new medications that has effects on two John R. Major cardiovascular risk factors. These are probably the two field of study preventable risk factors for bravery disease: external respiration and obesity. This [drug] represents a national leader medical transmutation for patients at risk of sum disease."

Tuesday, December 11, 2007

Fiction Businessperson Effective for Physical Property Loss, Vaporization Cessation.

The drug rimonabant (Acomplia) is effective for oppressiveness loss and vapour cessation, according to a public press group discussion held twenty-four hour period by the drug's business organization. "Those who stay on drug for a year show remarkable system of weights loss: 17 pounds," said Jean Pierre Despres, PhD, professor of food and sustenance sciences at Laval Body in Montreal, Canadian province, Canada. "And we saw a remarkable simplification in portion circuit of 8 cm." Rimonabant acts like marijuana in reverse gear, carving appetite and curbing the craving for nicotine in two large-scale clinical trials. The drug has "roughly doubled the odds of quitting ventilation," said Robert Anthenelli, MD, familiar professor of psychiatry at the Educational institution of Cincinnati Body of Medical specialty in Ohio. "We also found remarkably reduced postcessation metric gain: a 77% change of magnitude versus medicine.... These dual effects on vaporization cessation and reduced physical property gain make rimonabant a promising businessperson for treating baccy dependance." The weight-loss bailiwick enrolled more than 1,000 moderately obese men and women. Half of them had metabolic symptom. After a year on a 600 Kcal/day diet, nearly 75% of participants who received 20-mg doses of rimonabant lost at least 5% of their body exercising weight — and nearly half lost more than 10%. This is compared with about 25% of bailiwick participants who received medicine who lost more than 5% of their body importance. And only one in 10 lost more than 10% of their body exercising weight. That's impressive exercising weight loss for any clinical trial run. Plus, Dr. Despres said, citizenry who took rimonabant lost abdominal fat. Half of those who had metabolic symptom no longer had the assumption after communication.